Clinical Trial Update: Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

Phase 2 trial of autologous MSC-NTF cell therapy for amyotrophic lateral sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• NurOwn (MSC-NTF autologous cell therapy) (autologous mesenchymal stromal cells secreting neurotrophic factors)

Snippet

Sponsor: Brainstorm-Cell Therapeutics | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED